Clinical Trial Update: KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial [Phase 1]

View source ↗

Summary

Phase 1 trial of KDR2-2 Suspension Eyedrop for neovascular glaucoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Glaucoma

Drugs mentioned

• KDR2-2 Suspension Eyedrop (KDR2-2)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Neovascular Glaucoma, Neovascularization | Phase 1 | Status: ACTIVE_NOT_RECRUITING